A Phase II Study of Cisplatin in Patients with Biliary Tract Carcinoma
- 1 January 1994
- journal article
- clinical trial
- Published by S. Karger AG in Oncology
- Vol. 51 (6) , 515-517
- https://doi.org/10.1159/000227396
Abstract
A phase II study of cisplatin was performed in 13 previously untreated patients with unresectable biliary tract carcinoma. The drug was given intravenously at a dose of 80 mg/m2/day once every 4 weeks. Of 13 patients evaluated, 1 showed partial response lasting 3 months, while no patient showed complete response. Of 9 patients, whose serum level of carcinoembryonic antigen (CEA) was high (≥10 ng/ml) before treatment, 4 showed ≥50% reduction in serum CEA level after treatment. The current study indicates that cisplatin does not have significant antitumor activity against biliary tract carcinoma.Keywords
This publication has 0 references indexed in Scilit: